The global topical drugs market size is expected to reach USD 217.79 billion by 2030, according to a new report by Grand View Research Inc. The industry is expected to grow at a CAGR of 10.1% from 2022 to 2030. The key factors contributing to the industry growth include the increased prevalence of skin disorders coupled with strategic collaborations between key players. The increasing prevalence of skin infections, such as psoriasis, atopic dermatitis, and eczema, coupled with the rising demand for eye and ear therapies is expected to drive the demand for transdermal or dermal medicines during the forecast period. For instance, in October 2021, AbbVie Inc. received FDA approval for Vuity, a pilocarpine HCl ophthalmic solution for treating presbyopia.
In addition, according to the NCBI, the prevalence of psoriasis is nearly 1.92% and 1.5% among European and North American populations. The launch of topical medicines to treat skin diseases is also anticipated to propel the demand for dermal drugs. For instance, in September 2020, Bausch Health, Canada launched a novel antipsoriatic agent, Duobrii lotion for psoriasis patients.Advancements in technology and increased acquisitions and mergers activities among key players, such as Alcon, Inc. and Novartis AG, are anticipated to boost the industry's growth. For instance, in June 2022, Novartis AG acquired Kedalion Therapeutics, thereby acquiring AcuStream technology to facilitate accurate dermal delivery of ophthalmic medicines.
Moreover, in May 2022, Alcon Inc. acquired Eysuvis (loteprednol etabonate suspension) for topical ophthalmic use from Kala Pharmaceuticals, Inc., thereby adding to its existing portfolio of dry eye drugs.A high incidence of burn injuries is expected to render high utilization of topical medicines in treating burn injuries. For instance, according to the WHO, an estimated 11 million burn injuries occur annually worldwide, out of which about 180,000 cases are fatal. Various topical agents are used in treating burn injuries including silver sulfadiazine cream, bismuth-impregnated petroleum gauze, cerium nitrate, mafenide acetate, and nanocrystalline silver among others.
Request a free sample copy or view report summary: Topical Drugs Market Report
The semi-solid formulations segment dominated the market in 2021 owing to their high stability in atmospheric conditions and increased use of personalized drugs
The dermal segment dominated the industry in 2021 due to the increased utilization of transdermal patches to reduce tobacco consumption
The home care settings segment dominated the industry in 2021 due to the ease of administration among the geriatric population
North America was the largest regional market in 2021 due to strategic initiatives and collaborations among key players for the development & launch of dermal products
Grand View Research has segmented the global topical drugs market based on type, route of administration, end-use, and region:
Topical Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)
Semi-solid formulations
Creams
Ointments
Lotions
Gel
Pastes
Liquid Formulations
Suspensions
Solutions
Solid Formulations
Powders
Suppositories
Transdermal Products
Transdermal Patches
Transdermal Semi-solids
Topical Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Dermal Drug Delivery
Ophthalmic Drug Delivery
Rectal Drug Delivery
Vaginal Drug Delivery
Nasal Drug Delivery
Topical Drugs End-use Outlook (Revenue, USD Million, 2018 - 2030)
Home Care Settings
Hospitals & Clinics
Burn Centers
Other Facilities
Topical Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
Australia
South Korea
Singapore
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
List of Key Players of the Topical Drugs Market
Bayer AG
Cipla Inc.
GSK Group of Companies
Johnson & Johnson Private Ltd.
Novartis AG
Bausch Health Companies Inc.
HisamitsuPharmaceuticals Co. Inc.
Merck & Co. Inc.
Glenmark Pharmaceuticals Ltd.
MedPharm Ltd.
"The quality of research they have done for us has been excellent..."